Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026
Company

BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase

Fineline Cube Nov 10, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...

Company Deals Hospital

Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties

Fineline Cube Nov 10, 2023

US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore HSA Nod for Phase I Study of 177Lu-LNC1003

Fineline Cube Nov 10, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases

Fineline Cube Nov 10, 2023

Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm...

Company Drug

Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China

Fineline Cube Nov 10, 2023

China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of...

Company Deals

Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing

Fineline Cube Nov 10, 2023

China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon...

Company Medical Device

Sino Medical Sciences Technology Secures EU MDR Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Nov 10, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received Medical...

Company Deals

Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements

Fineline Cube Nov 10, 2023

Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with...

Company Deals

Bayer Secures Multiple Procurement Deals at the 6th CIIE

Fineline Cube Nov 10, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced...

Company Deals

ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions

Fineline Cube Nov 10, 2023

Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co.,...

Company Drug

Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia

Fineline Cube Nov 10, 2023

Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in...

Company Drug

ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study

Fineline Cube Nov 10, 2023

Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in...

Company Medical Device

Establishment Labs Receives NMPA Approval for Motiva Silicone Gel-Filled Breast Implants

Fineline Cube Nov 10, 2023

US-based medical technology company Establishment Labs Holdings Inc., (NASDAQ: ESTA) has announced that it has...

Company

AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones

Fineline Cube Nov 10, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third...

Company Drug

Novartis’ Remibrutinib Meets Milestones in Late-Stage Chronic Spontaneous Urticaria Studies

Fineline Cube Nov 10, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that two late-stage studies for its Bruton’s...

Company Deals

CStone Pharmaceuticals Enters Licensing Agreement with Allist Pharmaceuticals for Gavreto in China

Fineline Cube Nov 10, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced a licensing agreement with Allist Pharmaceuticals Co., Ltd,...

Company Drug

Roche’s Lymphoma Therapy Columvi Receives NMPA Approval for Adult Patients with Relapsed DLBCL

Fineline Cube Nov 9, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received market approval from...

Company Deals

Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004

Fineline Cube Nov 9, 2023

Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant...

Company

Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance

Fineline Cube Nov 9, 2023

Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered...

Company Drug

Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis

Fineline Cube Nov 9, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical unit, Janssen, has presented real-world efficacy data for...

Posts pagination

1 … 485 486 487 … 705

Recent updates

  • GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled
  • Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor
  • WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation
  • Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials
  • Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Legal / IP

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.